JP2012508740A - 変性α−シヌクレイン機能の治療のための組成物および方法 - Google Patents

変性α−シヌクレイン機能の治療のための組成物および方法 Download PDF

Info

Publication number
JP2012508740A
JP2012508740A JP2011536351A JP2011536351A JP2012508740A JP 2012508740 A JP2012508740 A JP 2012508740A JP 2011536351 A JP2011536351 A JP 2011536351A JP 2011536351 A JP2011536351 A JP 2011536351A JP 2012508740 A JP2012508740 A JP 2012508740A
Authority
JP
Japan
Prior art keywords
alkyl
alkenyl
substituted
piperazino
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011536351A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012508740A5 (enExample
Inventor
エイミー ビー． マニング−ボグ，
バージット シューレ，
ジェイ． ウィリアム ラングストン，
クリフ エー． リングウッド，
マイケル エス． マクグラス，
アラステー アリ アジール，
Original Assignee
パーキンソンズ インスティテュート
ザ ホスピタル フォー シック チルドレン
ニューラルタス ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パーキンソンズ インスティテュート, ザ ホスピタル フォー シック チルドレン, ニューラルタス ファーマシューティカルズ， インコーポレイテッド filed Critical パーキンソンズ インスティテュート
Publication of JP2012508740A publication Critical patent/JP2012508740A/ja
Publication of JP2012508740A5 publication Critical patent/JP2012508740A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011536351A 2008-11-14 2009-09-04 変性α−シヌクレイン機能の治療のための組成物および方法 Pending JP2012508740A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19924308P 2008-11-14 2008-11-14
US61/199,243 2008-11-14
PCT/US2009/056116 WO2010056413A2 (en) 2008-11-14 2009-09-04 COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED α-SYNUCLEIN FUNCTION

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015076943A Division JP2015127343A (ja) 2008-11-14 2015-04-03 変性α−シヌクレイン機能の治療のための組成物および方法

Publications (2)

Publication Number Publication Date
JP2012508740A true JP2012508740A (ja) 2012-04-12
JP2012508740A5 JP2012508740A5 (enExample) 2012-10-18

Family

ID=42170611

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011536351A Pending JP2012508740A (ja) 2008-11-14 2009-09-04 変性α−シヌクレイン機能の治療のための組成物および方法
JP2015076943A Pending JP2015127343A (ja) 2008-11-14 2015-04-03 変性α−シヌクレイン機能の治療のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015076943A Pending JP2015127343A (ja) 2008-11-14 2015-04-03 変性α−シヌクレイン機能の治療のための組成物および方法

Country Status (9)

Country Link
US (2) US20120052053A1 (enExample)
EP (1) EP2361089A4 (enExample)
JP (2) JP2012508740A (enExample)
CN (1) CN102245180A (enExample)
AU (1) AU2009314447A1 (enExample)
BR (1) BRPI0920498A2 (enExample)
CA (1) CA2745451A1 (enExample)
GB (1) GB2480159A (enExample)
WO (1) WO2010056413A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2014162737A1 (ja) * 2013-04-02 2017-02-16 学校法人同志社 タウ凝集阻害剤
JP2019513231A (ja) * 2016-03-25 2019-05-23 ジェンザイム・コーポレーション タンパク質症のバイオマーカーおよびその使用
WO2020231024A1 (ko) * 2019-05-14 2020-11-19 주식회사 노브메타헬스 고시페틴을 포함하는 퇴행성 뇌질환 예방 또는 치료용 조성물

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011505374A (ja) * 2007-11-29 2011-02-24 ザ・ホスピタル・フォー・シック・チルドレン リソソーム障害を処置するための組成物および方法
US9265735B2 (en) * 2010-11-30 2016-02-23 New York University Methods for screening to identify therapeutic agents for Alzheimer's disease and use thereof
EP2533051A1 (en) * 2011-06-06 2012-12-12 Centogene GmbH Method for the diagnosis of Gaucher's disease
EP2739304A4 (en) * 2011-08-04 2015-06-03 Univ Ramot PARTICLES FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
CN103120697B (zh) * 2011-11-18 2015-10-07 复旦大学 鳞片酸在制备抗肿瘤药物中的应用
CN103120696A (zh) * 2011-11-18 2013-05-29 复旦大学 羊角衣酸在制备抗肿瘤药物中的应用
CN104069263A (zh) * 2013-03-27 2014-10-01 中国科学院上海药物研究所 一种用于治疗阿尔茨海默病的制剂及其制备方法
CN105796579A (zh) * 2014-12-31 2016-07-27 中国科学院兰州化学物理研究所 抗老年性脑痴呆药物
US10702571B2 (en) 2015-12-03 2020-07-07 The University Of North Carolina At Pembroke Materials for cathepsin B enhancement and methods of use
CN108348557A (zh) * 2016-03-28 2018-07-31 心悦生医股份有限公司 含有鞣酸的组合物及其用途
CN105748460B (zh) * 2016-04-07 2018-11-02 大连医科大学附属第二医院 一种治疗老年痴呆的药物
ES2650175B1 (es) * 2016-04-15 2019-02-04 Servicio Andaluz De Salud Tratamiento de enfermedades neurodegenerativas
US10064833B2 (en) 2016-08-04 2018-09-04 Syneurx International (Taiwan) Corp. Compositions containing benzoate compound and tannic acid for treating central nervous system disorders
CN108143738A (zh) * 2016-12-02 2018-06-12 中国科学院大连化学物理研究所 一种治疗阿尔茨海默症的药物组合物及其制备和应用
CN107823198A (zh) * 2017-11-16 2018-03-23 黑龙江葆纳生物科技有限责任公司 北美圣草素在制备治疗阿尔茨海默病药物中的应用
KR20200097255A (ko) * 2017-12-07 2020-08-18 신유알엑스 인터내셔널 (타이완) 코포레이션 탄닌산 조성물을 제조하기 위한 개선된 풍부화 방법
WO2019126739A1 (en) 2017-12-21 2019-06-27 Shepherd Therapeutics, Inc. Pyrvinium pamoate anti-cancer therapies
US11766423B2 (en) 2018-03-01 2023-09-26 The Johns Hopkins University 2,6-dimethoxy-4-(5-phenyl-4-thiophene-2-yl-1H-imidazol-2-yl)-phenol (DPTIP) a small molecule inhibitor of neutral sphingomyelinase 2 (nSMase-2) for the treatment of neurodegenerative and oncologic diseases
WO2020144753A1 (ja) * 2019-01-09 2020-07-16 公立大学法人大阪 神経変性疾患の予防又は治療薬
US11154531B2 (en) 2020-02-08 2021-10-26 Syneurx International (Taiwan) Corp. Compounds and pharmaceutical uses thereof
WO2021188575A1 (en) * 2020-03-16 2021-09-23 Coe William B Dietary supplement comprising aldehyde functional monoterpenoids
US10993958B1 (en) 2020-03-16 2021-05-04 William B. Coe Aldehyde functional monoterpenoids for the treatment of coronavirus infection
KR20230004765A (ko) 2020-04-23 2023-01-06 신유알엑스 인터내셔널 (타이완) 코포레이션 화합물 및 이의 약학적 용도
WO2022104011A1 (en) * 2020-11-12 2022-05-19 Yumanity Therapeutics, Inc. Methods for the treatment of neurological disorders
CN112870250B (zh) * 2021-01-21 2022-08-12 广东盛普生命科技有限公司 防治器官纤维化的组合物及其应用与制剂
CN112704680B (zh) * 2021-01-21 2022-08-02 广东盛普生命科技有限公司 预防和/或治疗器官纤维化的组合物及其应用与制剂
WO2024026390A2 (en) * 2022-07-28 2024-02-01 Wylder Nation Foundation Compositions and methods for diagnosing, treating, and preventing lysosomal storage diseases
KR20240023004A (ko) * 2022-08-12 2024-02-20 포항공과대학교 산학협력단 고시페틴을 포함하는 지방간 개선용 조성물
CN115417789B (zh) * 2022-09-03 2023-08-04 郑州大学 一种治疗帕金森氏病的化合物、其制备方法以及复方药物组合物和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020147197A1 (en) * 1999-10-08 2002-10-10 Newman Michael J. Methods and compositions for enhancing pharmaceutical treatments
WO2006133446A2 (en) * 2005-06-08 2006-12-14 Amicus Therapeutics, Inc. Treatment of cns disorders associated with mutations in genes encoding lysosomal enzymes
JP2007314540A (ja) * 2006-05-24 2007-12-06 Amicus Therapeutics Inc イソファゴミンの酒石酸塩および使用方法
WO2007150064A2 (en) * 2006-06-23 2007-12-27 Amicus Therapeutics, Inc. METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS BY ENHANCING THE ACTIVITY OF β-GLUCOCEREBROSIDASE

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007500219A (ja) * 2003-05-16 2007-01-11 アンビット バイオサイエンシス コーポレーション 複素環化合物およびその使用法
WO2007003941A1 (en) * 2005-07-06 2007-01-11 Cambridge Enterprise Limited Modulation of autophagy by calpain inhibition
WO2008031831A2 (en) * 2006-09-12 2008-03-20 Neurosearch A/S Pharmaceutical compositions comprising combinations of an ampa/kainate antagonistic compound and an inhibitor of a multidrug resistance protein

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020147197A1 (en) * 1999-10-08 2002-10-10 Newman Michael J. Methods and compositions for enhancing pharmaceutical treatments
WO2006133446A2 (en) * 2005-06-08 2006-12-14 Amicus Therapeutics, Inc. Treatment of cns disorders associated with mutations in genes encoding lysosomal enzymes
JP2007314540A (ja) * 2006-05-24 2007-12-06 Amicus Therapeutics Inc イソファゴミンの酒石酸塩および使用方法
WO2007150064A2 (en) * 2006-06-23 2007-12-27 Amicus Therapeutics, Inc. METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS BY ENHANCING THE ACTIVITY OF β-GLUCOCEREBROSIDASE

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6014051467; Ｅｕｒｏｐｅａｎ　Ｈｕｍａｎ　Ｇｅｎｅｔｉｃｓ　Ｃｏｎｆｅｒｅｎｃｅ　の要旨 , 2007 *
JPN7013003965; Ｊ　Ｎｅｕｒｏｃｈｅｍ，　２００８　Ｊｕｎ，　１０５（５），　ｐ．１６５６-６７ *
JPN7013003966; Ｍｅｄ　Ｈｙｐｏｔｈｅｓｅｓ，　１９９４，　４３（３），　ｐ．１３２-４ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2014162737A1 (ja) * 2013-04-02 2017-02-16 学校法人同志社 タウ凝集阻害剤
US9907799B2 (en) 2013-04-02 2018-03-06 The Doshisha Tau aggregation inhibitor
JP2019513231A (ja) * 2016-03-25 2019-05-23 ジェンザイム・コーポレーション タンパク質症のバイオマーカーおよびその使用
WO2020231024A1 (ko) * 2019-05-14 2020-11-19 주식회사 노브메타헬스 고시페틴을 포함하는 퇴행성 뇌질환 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
GB201108374D0 (en) 2011-06-29
JP2015127343A (ja) 2015-07-09
CN102245180A (zh) 2011-11-16
CA2745451A1 (en) 2010-05-20
EP2361089A4 (en) 2012-08-22
AU2009314447A1 (en) 2010-05-20
EP2361089A1 (en) 2011-08-31
US20120052053A1 (en) 2012-03-01
GB2480159A (en) 2011-11-09
US20150044193A1 (en) 2015-02-12
BRPI0920498A2 (pt) 2019-09-24
WO2010056413A2 (en) 2010-05-20

Similar Documents

Publication Publication Date Title
JP2015127343A (ja) 変性α−シヌクレイン機能の治療のための組成物および方法
US8252789B2 (en) Compositions and methods for treating lysosomal disorders
AU2017279780B2 (en) Combination of a compound having the ability to rearrange a lysosomal enzyme and ambroxol and/or a derivative of ambroxol
Lin et al. N-Octyl-β-valienamine up-regulates activity of F213I mutant β-glucosidase in cultured cells: a potential chemical chaperone therapy for Gaucher disease
Platt et al. Substrate reduction therapy
US20140235649A1 (en) Use of phosphatase inhibitors or histone deacetylase inhibitors to treat diseases characterized by loss of protein function
van Echten-Deckert et al. Sphingolipid metabolism–an ambiguous regulator of autophagy in the brain
Mei et al. Sphingolipid metabolism in brain insulin resistance and neurological diseases
JP2015212291A (ja) グルコシルセラミドシンターゼの阻害剤としての非晶質及び結晶型のｇｅｎｚ１１２６３８ヘミ酒石酸塩
US20160075651A1 (en) Glycolipid inhibition using iminosugars
US7662838B2 (en) Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof
LeVine et al. Substrate reduction therapy for krabbe disease: exploring the repurposing of the antibiotic D-Cycloserine
US12029706B2 (en) Methods for treating mucopolysaccharidosis
AU2014265137A1 (en) Compositions and methods for the treatment of altered alpha-synuclein function
US10519157B2 (en) Deuterated compounds for treating Fabry, Gaucher, Parkinson's and related diseases and conditions, and compositions and methods thereof
JP2025136965A (ja) 疼痛治療剤
Fan et al. Pharmacological chaperone therapy for fabry disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120903

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120903

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131029

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140128

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140430

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141203